Statements (96)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:2020
gptkb:FDA gptkb:United_States February 2020 |
| gptkbp:available_on |
prescription medication
|
| gptkbp:bioavailability |
not applicable (IV administration)
|
| gptkbp:chemical_formula |
C6490 H10080 N1716 O2016 S44
|
| gptkbp:clinical_trial |
Phase 3
Phase III positive results PROMISE-1 PROMISE-2 improved patient-reported outcomes reduced migraine frequency NCT02614124 NCT02438826 NCT02916849 |
| gptkbp:clinical_use |
chronic migraine
episodic migraine preventive treatment for migraines preventing migraine attacks |
| gptkbp:contraindication |
hypersensitivity to components
hypersensitivity to the drug hypersensitivity to eptinezumab active or history of severe allergic reactions |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
gptkb:Software_Solutions
solution for infusion |
| gptkbp:drug_interactions |
none significant
|
| gptkbp:duration |
ongoing as needed
|
| gptkbp:effective_date |
gptkb:2020
|
| gptkbp:financial_stability |
24 months at -20° C
|
| gptkbp:financial_support |
available
available through Abb Vie |
| gptkbp:formulation |
lyophilized powder for reconstitution
sterile solution for infusion |
| https://www.w3.org/2000/01/rdf-schema#label |
Eptinezumab
|
| gptkbp:indication |
migraine prevention
chronic migraine episodic migraine preventive treatment of migraine |
| gptkbp:invention |
gptkb:Abb_Vie_Inc.
2029 patented |
| gptkbp:is_effective_against |
improves quality of life
reduces acute medication use reduces monthly migraine days |
| gptkbp:lifespan |
approximately 27 days
|
| gptkbp:manufacturer |
Lilly
|
| gptkbp:market |
ongoing
|
| gptkbp:market_launch |
gptkb:2020
|
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States Vyepti |
| gptkbp:mechanism_of_action |
CGRP receptor antagonist
|
| gptkbp:patient_population |
adults
|
| gptkbp:pharmacokinetics |
long half-life
CGRP inhibition linear pharmacokinetics |
| gptkbp:price |
high cost
|
| gptkbp:provides_guidance_on |
included in migraine management guidelines
|
| gptkbp:requires |
available on FDA website
|
| gptkbp:research_areas |
neurology
|
| gptkbp:research_focus |
chronic migraine treatment
episodic migraine treatment preventive treatment for migraines |
| gptkbp:rounds |
primarily through the kidneys
|
| gptkbp:route_of_administration |
intravenous
subcutaneous |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:service_frequency |
every 3 months
once every three months |
| gptkbp:side_effect |
dizziness
fatigue nausea constipation dry mouth injection site reactions hypersensitivity reactions nasopharyngitis |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
CGRP (Calcitonin Gene-Related Peptide)
CGRP (calcitonin gene-related peptide) |
| gptkbp:trade |
Vyepti
|
| gptkbp:type_of_care |
high adherence rates
|
| gptkbp:type_of_insurance |
may vary by plan
|
| gptkbp:used_for |
migraine prevention
preventing migraine |
| gptkbp:weight |
146 k Da
|
| gptkbp:bfsParent |
gptkb:Biogen_Idec
gptkb:Alder_Bio_Pharmaceuticals |
| gptkbp:bfsLayer |
5
|